Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cerivastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 4/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | PDE6D | O43924 | 1/20 | 0.58 |
| ▸ | GCGR | P47871 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.49 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.49 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | RXRA | P19793 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cerivastatin SCHEMBL16347 | 1.00 | HMGCR (1.00) | HMGCRTBXA2RADRA1AESR1CHRM1 | |
| Cerivastatin SCHEMBL16346 | 1.00 | HMGCR (1.00) | HMGCRTBXA2RADRA1AESR1CHRM1 | |
| Cerivastatin SCHEMBL14879523 | 1.00 | HMGCR (1.00) | HMGCRTBXA2RADRA1AESR1CHRM1 | |
| Cerivastatin SCHEMBL5508954 | 1.00 | HMGCR (1.00) | HMGCRTBXA2RADRA1AESR1CHRM1 | |
| Cerivastatin SCHEMBL6241954 | 1.00 | HMGCR (1.00) | HMGCRTBXA2RADRA1AESR1CHRM1 | |
| Cerivastatin SCHEMBL6241950 | 1.00 | HMGCR (1.00) | HMGCRTBXA2RADRA1AESR1CHRM1 | |
| Cerivastatin SCHEMBL10024041 | 1.00 | HMGCR (1.00) | HMGCRTBXA2RADRA1AESR1CHRM1 | |
| Cerivastatin SCHEMBL29379484 | 1.00 | HMGCR (1.00) | HMGCRTBXA2RADRA1AESR1CHRM1 | |
| Cerivastatin SCHEMBL5508956 | 1.00 | HMGCR (1.00) | HMGCRTBXA2RADRA1AESR1CHRM1 | |
| Cerivastatin SCHEMBL6268472 | 1.00 | HMGCR (1.00) | HMGCRTBXA2RADRA1AESR1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240189221-A1 | METHODS AND FORMULATIONS FOR TREATING VASCULAR DISEASE | ENDOPERFUSION SOLUTIONS, LLC | 2024-06-13 | — | — | US | disclosed |
| EP-3386503-B1 | KITS FOR TREATING VASCULAR DISEASE | ENDOPERFUSION SOLUTIONS LLC (US) | 2022-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189221-A1 | METHODS AND FORMULATIONS FOR TREATING VASCULAR DISEASE | LIPG, APOB, LIPA | HMGCR 5/4885TBXA2R 12/4885ADRA1A 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.